Navidea Biopharmaceuticals (NAVB) 10-Q 9 Nov 17 2017 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Nov. 01, 2017
Document Information [Line Items]
Entity Registrant Name	NAVIDEA BIOPHARMACEUTICALS, INC.
Entity Central Index Key	810,509
Trading Symbol	navb
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		162,256,646
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Amendment Flag	false

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash	$ 4,619,649	$ 1,539,325
Restricted cash		5,001,253
Available-for-sale securities	1,998,800
Accounts and other receivables	8,042,691	203,016
Inventory, net		96,208
Prepaid expenses and other	504,971	842,220
Assets associated with discontinued operations, current		3,144,247
Total current assets	15,166,111	10,826,269
Property and equipment	1,712,342	3,232,372
Less accumulated depreciation and amortization	1,399,040	2,051,787
Property and equipment, net	313,302	1,180,585
Patents, trademarks and license agreements	480,404	146,685
Less accumulated amortization	14,832
Patents, trademarks and license agreements, net	465,572	146,685
Guaranteed earnout receivable	6,445,390
Other assets	215,332	202,882
Assets associated with discontinued operations		105,255
Total assets	22,605,707	12,461,676
Current liabilities:
Accounts payable	1,231,075	5,165,385
Accrued liabilities and other	2,494,115	7,872,893
Notes payable, current	1,981,676	51,957,913
Terminated lease liability, current	144,231
Liabilities associated with discontinued operations, current	33,141	4,865,597
Total current liabilities	5,884,238	69,861,788
Notes payable		9,641,179
Terminated lease liability	629,445
Other liabilities	76,850	624,922
Total liabilities	6,590,533	80,127,889
Commitments and contingencies (Note 12)
Stockholders’ equity (deficit):
Preferred stock; $.001 par value; 5,000,000 shares authorized; no shares issued or outstanding at September 30, 2017 and December 31, 2016
Common stock; $.001 par value; 300,000,000 shares authorized; 162,206,646 and 155,762,729 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	162,207	155,763
Additional paid-in capital	331,036,285	326,564,148
Accumulated deficit	(315,850,836)	(394,855,034)
Accumulated other comprehensive loss	(1,200)
Total Navidea stockholders' equity (deficit)	15,346,456	(68,135,123)
Noncontrolling interest	668,718	468,910
Total stockholders’ equity (deficit)	16,015,174	(67,666,213)
Total liabilities and stockholders’ equity (deficit)	$ 22,605,707	$ 12,461,676

Consolidated Balance Sheets (C3

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	162,206,646	155,762,729
Common stock, shares outstanding (in shares)	162,206,646	155,762,729

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue:
Tc99m tilmanocept sales revenue			$ 17,601		$ 30,800
Tc99m tilmanocept license revenue			1,295,625	100,000	1,795,625
Grant and other revenue		223,669	510,974	1,315,298	2,113,420
Total revenue		223,669	1,824,200	1,415,298	3,939,845
Cost of goods sold			2,889		5,185
Gross profit		223,669	1,821,311	1,415,298	3,934,660
Operating expenses:
Research and development		874,547	919,441	2,765,695	5,010,923
Selling, general and administrative		1,734,707	1,811,680	9,006,725	5,832,623
Total operating expenses		2,609,254	2,731,121	11,772,420	10,843,546
Loss from operations	[1]	(2,385,585)	(909,810)	(10,357,122)	(6,908,886)
Other income (expense):
Interest income (expense), net		76,050	159	144,811	(2,076)
Equity in loss of R-NAV, LLC					(15,159)
Loss on disposal of investment in R-NAV, LLC					(39,732)
Change in fair value of financial instruments			(839,298)	153,357	1,755,989
Loss on extinguishment of debt				(1,314,102)
Other, net		(6,979)	(12,498)	(45,256)	(49,916)
Total other income (expense), net		69,071	(851,637)	(1,061,190)	1,649,106
Loss before income taxes		(2,316,514)	(1,761,447)	(11,418,312)	(5,259,780)
Benefit from income taxes		775,750	0	3,861,156
Loss from continuing operations		(1,540,764)	(1,761,447)	(7,557,156)	(5,259,780)
Discontinued operations, net of tax effect:
Income (loss) from discontinued operations		5,399	1,701,911	(332,838)	(5,167,312)
Gain on sale		145,877		86,894,000
Net income (loss)		(1,389,488)	(59,536)	79,004,006	(10,427,092)
Less loss attributable to noncontrolling interest		(23)	(159)	(192)	(516)
Net income (loss) attributable to common stockholders		$ (1,389,465)	$ (59,377)	$ 79,004,198	$ (10,426,576)
Income (loss) per common share (basic):
Continuing operations (in dollars per share)		$ (0.01)	$ (0.01)	$ (0.05)	$ (0.03)
Discontinued operations (in dollars per share)			0.01	0.54	(0.04)
Attributable to common stockholders (in dollars per share)		$ (0.01)		$ 0.49	$ (0.07)
Weighted average shares outstanding (basic) (in shares)		162,006,646	155,481,278	161,437,276	155,390,911
Income (loss) per common share (diluted):
Continuing operations (in dollars per share)		$ (0.01)	$ (0.01)	$ (0.05)	$ (0.03)
Discontinued operations (in dollars per share)			0.01	0.52	(0.04)
Attributable to common stockholders (in dollars per share)		$ (0.01)		$ 0.47	$ (0.07)
Weighted average shares outstanding (diluted) (in shares)		162,006,646	155,481,278	165,914,473	155,390,911
[1]	Income (loss) from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Net income (loss)	$ (1,389,488)	$ (59,536)	$ 79,004,006	$ (10,427,092)
Unrealized loss on available-for-sale securities	(172)		(1,200)
Comprehensive income (loss)	$ (1,389,660)	$ (59,536)	$ 79,002,806	$ (10,427,092)

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) - 9 months ended Sep. 30, 2017 - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2016	155,762,729
Balance at Dec. 31, 2016	$ 155,763	$ 326,564,148	$ (394,855,034)		$ 468,910	$ (67,666,213)
Issued stock in payment of Board retainers (in shares)	16,406
Issued stock in payment of Board retainers	$ 17	10,483				10,500
Issued stock in payment of employee bonuses (in shares)	710,353
Issued stock in payment of employee bonuses	$ 710	368,632				369,342
Issued stock upon exercise of warrants (in shares)	5,411,850
Issued stock upon exercise of warrants	$ 5,412	48,707				54,119
Issued warrants in connection with Asset Sale		3,337,187				3,337,187
Issued warrants for extension of license agreement		333,719				$ 333,719
Issued stock to 401(k) plan (in shares)	105,308					105,308
Issued stock to 401(k) plan	$ 105	53,602				$ 53,707
Issued restricted stock (in shares)	200,000
Issued restricted stock	$ 200					200
Stock compensation expense		319,807				319,807
Net income			79,004,198		(192)	79,004,006
Unrealized loss on available-for-sale securities				$ (1,200)		(1,200)
Total comprehensive income						79,002,806
Reclassification of funds invested (see Note 8)					200,000	200,000
Balance (in shares) at Sep. 30, 2017	162,206,646
Balance at Sep. 30, 2017	$ 162,207	$ 331,036,285	$ (315,850,836)	$ (1,200)	$ 668,718	$ 16,015,174

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net income (loss)	$ 79,004,006	$ (10,427,092)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	212,077	378,834
Loss on disposal and abandonment of assets	806,710	136,719
Gain on forgiveness of accounts payable		(85,355)
Change in inventory reserve		43,354
Amortization of debt discount and issuance costs		77,964
Debt discount and issuance costs written off		1,955,541
Prepayment premium and debt collection fees related to long term debt		2,923,271
Compounded interest on long term debt	211,443	1,367,259
Stock compensation expense	319,807	310,642
Loss on disposal of investment in R-NAV, LLC		39,732
Change in fair value of financial instruments	(153,357)	(1,755,989)
Issued warrants in connection with Asset Sale	3,337,187
Value of stock issued to directors	10,500	56,609
Value of stock issued to employees	369,342
Value of stock issued to 401(k) plan for employer matching contributions	53,707	120,800
Other	65
Changes in operating assets and liabilities:
Accounts and other receivables	(12,686,071)	210,536
Inventory	1,470,826	(195,330)
Prepaid expenses and other assets	495,434	11,465
Accounts payable	(5,897,416)	3,212,632
Accrued and other liabilities	(5,507,487)	4,113,403
Deferred revenue	(2,315,037)	(1,195,911)
Net cash provided by operating activities	59,731,736	1,299,084
Cash flows from investing activities:
Purchases of available-for-sale securities	(2,200,000)
Maturities of available-for-sale securities	200,000
Purchases of equipment	(31,417)	(1,847)
Proceeds from sales of equipment		45,000
Payments on disposal of investment in R-NAV, LLC		(110,000)
Proceeds from disposal of investment in R-NAV, LLC		27,623
Net cash used in investing activities	(2,031,417)	(39,224)
Cash flows from financing activities:
Proceeds from issuance of common stock	54,319	140
Payment of debt-related costs		(3,923,271)
Principal payments on notes payable	(59,675,502)	(189,163)
Release of restricted cash held for payment against debt	5,001,188	(3,501,247)
Payments under capital leases		(2,154)
Net cash used in financing activities	(54,619,995)	(7,615,695)
Net increase (decrease) in cash	3,080,324	(6,355,835)
Cash, beginning of period	1,539,325	7,166,260
Cash, end of period	$ 4,619,649	$ 810,425

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1. Summary of Significant Accounting Policies a. Basis of Presentation: The information presented as of September 30, 2017 three nine September 30, 2017 2016 September 30, 2017 not December 31, 2016, 10 Our consolidated financial statements include the accounts of Navidea and our wholly owned subsidiaries, Navidea Biopharmaceuticals Limited and Cardiosonix Ltd, as well as those of our majority-owned subsidiary, Macrophage Therapeutics, Inc. ( “MT”). All significant inter-company accounts were eliminated in consolidation. Cardiosonix was legally dissolved in September 2017. May 2016, not On March 3, 2017, November 23, 2016, ( 414, 414” ’s radioactive diagnostic agent marketed under the Lymphoseek ® Upon closing of the Asset Sale, the Supply and Distribution Agreement, dated November 15, 2007 ( 414 no Our consolidated balance sheets and statements of operations have been reclassified, as required, for all periods presented to reflect the Business as a discontinued operation. Cash flows associated with the operation of the Business have been combined with operating, investing and financing cash flows, as appropriate, in our consolidated statement s of cash flows. See Note 3. b. Financial Instruments and Fair Value: In accordance with current accounting standards, the fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value, giving the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 3 three Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2 – Quoted prices in markets that are not Level 3 – Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. A financial instrument ’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. In determining the appropriate levels, we perform a detailed analysis of the assets and liabilities whose fair value is measured on a recurring basis. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no 3. 4. The following methods and assumptions were used to estimate the fair value of each class of financial instruments: ( 1 Cash, restricted cash, available-for-sale securities, accounts and other receivables, and accounts payable: The carrying amounts approximate fair value because of the short maturity of these instruments. ( 2 Notes payable: At September 30, 2017 December 31, 2016, 3 September 30, 2017, zero 10. ( 3 Derivative liabilities: Derivative liabilities are related to certain outstanding warrants which are recorded at fair value. Derivative liabilities totaling $63,000 September 30, 2017 December 31, 2016 September 30, 2017 December 31, 2016 4. ( 4 Warrants: In March 2017, 414 five 10 1 $1.50 414 $3.3 three March 31, 2017. $334,000, three March 31, 2017. 14. c. Revenue Recognition: We currently generate revenue primarily from grants to support various product development initiatives. We generally recognize grant revenue when expenses reimbursable under the grants have been paid and payments under the grants become contractually due. We also earn revenues related to our licensing and distribution agreements. The terms of these agreements may not $2.0 March 2015. id not not not two $417,000 September 2016, d. Recent ly Adopted Accounting Standards : March 2016, No. 2016 09, Compensation – Stock Compensation (Topic 178 2016 09 2016 09 December 15, 2016, 2016 09 January 1, 2017 not ● As of December 31, 2016, $15.3 December 31, 2016, zero 2016 09. ● Due to the full valuation allowance for the Company’s tax provision, these APIC NOLs have never been recorded in additional paid-in-capital. The Company does not ● The Company will continue to recognize forfeitures through estimates consistent with our past practices as opposed to when they occur. ● The Company already classifies cash paid to taxing authorities arising from the withholding of shares from employees in cash flows from financing activities. e. Recent Accounting Standards: In May 2014, No. 2014 09, Revenue from Contracts with Customers (Topic 606 2014 09 2014 09 five may 2014 09, 606 2014 09 2014 09 2014 09 December 15, 2017, Following the sale of the Business to Cardinal Health 414 March 2017, we generate revenue primarily from grants to support certain of our product development programs. Such grant revenues are recognized only after expenses reimbursable under the grants have been paid. We also earn revenues related to our licensing and distribution agreements. The consideration we are eligible to receive under our licensing and distribution agreements typically includes upfront payments, reimbursement for research and development costs, milestone payments, and royalties. Each licensing and distribution agreement is unique and will require separate assessment using the five 2014 09. 2014 09, not 2014 09 January 1, 2018. In January 2017, No. 2017 01, 805 2017 01 not not not 2017 01 1 2 2017 01 December 15, 2017, 2017 01 No 2017 01. 2017 01 In May 2017, No. 2017 09, Compensation-Stock Compensation (Topic 718 2017 09 1 not not 2 3 2017 09 December 15, 2017. 2017 09. 2017 09 In September 2017, No. 2017 13, Revenue Recognition (Topic 605 606 840 842 2017 13 July 2017 2017 13

Note 2 - Liquidity

Note 2 - Liquidity	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	2. Liquidity Prior to the Asset Sale to Cardinal Health 414 March 2017, our Term Loan Agreement with Capital Royalty Partners II L.P. and certain of its affiliates (collectively, “CRG”) (the “CRG Loan Agreement”). In addition to the security interest in our assets, the CRG Loan Agreement included covenants that imposed significant requirements on us. An event of default would have entitled CRG to accelerate the maturity of our indebtedness, increase the interest rate from 14% 18% 2016, June 22, 2016, one $4.1 On March 3, 2017, 414 February 22, 2017. March 3, 2017, $59 no no $47 no $66 414 posted a $7 414’s $12 one 414 414 $59 first 414, 414 414 414 414, 414 $2 $3 In addition, the Company previously was a party to a Loan Agreement with Platinum-Montaur Life Sciences LLC (“Platinum-Montaur”), an affiliate of Platinum Management (NY) LLC, Platinum Partners Value Arbitrage Fund L.P., Platinum Partners Liquid Opportunity Master Fund L.P., Platinum Liquid Opportunity Management (NY) LLC, and Montsant Partners LLC (collectively, “Platinum”) (the “Platinum Loan Agreement”) and a Third Amended and Restated Promissory Note (“Platinum Note”) given by Navidea in favor of Platinum-Montaur. In connection with the closing of the Asset Sale to Cardinal Health 414, $7.7 ’s liabilities, obligations and indebtedness under the Platinum Loan Agreement between the Company and Platinum-Montaur, which was purportedly transferred by Platinum-Montaur to PPCO. The Company was informed by Platinum Partners Value Arbitrage Fund LP (“PPVA”) that it was the owner of the balance of the Platinum Note. Such balance of approximately $1.9 not On March 2, 2017, no The remaining balance of the Platinum Note would have matured under its terms in September 2017, not Based on our current working capital and our projected cash burn, including the potential for the Company to pay up to an additional $7 twelve 10

Note 3 - Discontinued Operation

Note 3 - Discontinued Operations	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	3 . Discontinued Operations On March 3, 2017, the sale to Cardinal Health 414 ® In exchange for the Acquired Assets, Cardinal Health 414 $80.6 $3 , (ii) assumed certain liabilities of the Company associated with the Product as specified in the Purchase Agreement, and (iii) agreed to make periodic earnout payments (to consist of contingent payments and milestone payments which, if paid, will be treated as additional purchase price) to the Company based on net sales derived from the purchased Product subject, in each case, to Cardinal Health 414’s no $230 ten $20.1 $6.7 three $3 414 third We recorded a net gain on the sale of the Business of $86.9 nine September 30, 2017, $16.5 $3.3 414, $2.0 $800,000 $6.4 As a result of the Asset Sale, we reclassified certain assets and liabilities as assets and liabilities associated with discontinued operations. The following assets and liabilities have been segregated and included in assets associated with discontinued operations or liabilities associated with discontinued operations, as appropriate, in the consolidated balance sheets: September 30 , 2017 December 31, 2016 Accounts and other receivables $ — $ 1,598,994 Inventory, net — 1,374,618 Prepaid expenses — 170,635 Assets associated with discontinued operations, current — 3,144,247 Property and equipment, net of accumulated depreciation — 70,973 Patents and trademarks, net of accumulated amortization — 34,282 Assets associated with discontinued operations, noncurrent — 105,255 Total a ssets associated with discontinued operations $ — $ 3,249,502 Accounts payable $ 232 $ 1,957,938 Accrued liabilities 32,909 607,659 Deferred revenue — 2,300,000 Liabilities associated with discontinued operations, current $ 33,141 $ 4,865,597 In addition, we reclassified certain revenues and expenses related to the Business to discontinued operations for all periods presented , including interest expense related to the CRG and Platinum debt obligations as required by current accounting guidance. The following amounts have been segregated from continuing operations and included in discontinued operations in the consolidated statements of operations: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Revenue: Lymphoseek sales revenue $ — $ 6,672,489 $ 2,917,213 $ 14,673,689 Grant and other revenue — 385 — 575 Total revenue — 6,672,874 2,917,213 14,674,264 Cost of goods sold — 918,928 364,192 2,012,301 Gross profit — 5,753,946 2,553,021 12,661,963 Operating expenses: Research and development (5,951 ) 356,612 382,070 1,450,231 Selling, general and administrative — 1,129,093 805,464 4,092,951 Total operating expenses (5,951 ) 1,485,705 1,187,534 5,543,182 Income from discontinued operations 5,951 4,268,241 1,365,487 7,118,781 Interest expense — (2,566,330 ) (1,718,506 ) (12,286,093 ) Income (l oss) before income taxes 5,951 1,701,911 (353,019 ) (5,167,312 ) Benefit from (provision for) income taxes (552 ) — 20,181 — Income (l oss) from discontinued operations $ 5,399 $ 1,701,911 $ (332,838 ) $ (5,167,312 )

Note 4 - Fair Value

Note 4 - Fair Value	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Fair Value Disclosures [Text Block]	4 . Fair Value The Company has been informed by PPVA that it is the owner of the balance of the Platinum Note. Such balance of approximately $1.9 not September 2017, not If determined to be the obligee under the Platinum Note, Platinum or Dr. Goldberg would have had the right to convert all or any portion of the unpaid principal or unpaid interest accrued on all draws under the Platinum credit facility, under certain circumstances. The Platinum embedded option to convert such debt into common stock is recorded at fair value on the consolidated balance sheets and deemed to be a derivative instrument as the amount of shares to be issued upon conversion is indeterminable. The estimated fair value of the conversion option of the Platinum Note payable is approximately $0 $153,000 September 30, 2017 December 31, 2016, September 2017, no MT issued warrants to purchase MT Common Stock with certain characteristics including a net settlement provision that require the warrants to be accounted for as a derivative liability at fair value on the consolidated balance sheets. The estimated fair value of the MT warrants is $63,000 both September 30, 2017 December 31, 2016, 1 3 The following tables set forth, by level, financial liabilities measured at fair value on a recurring basis: Liabilities Measured at Fair Value on a Recurri ng Basis as of September 30, 2017 Description Quoted Prices in Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Platinum conversion option $ — $ — $ — $ — Liability related to MT warrants — — 63,000 63,000 Liabilities Measured at Fair Value on a Recurri ng Basis as of December 31, 2016 Description Quoted Prices in Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Platinum conversion option $ — $ — $ 153,357 $ 153,357 Liability related to MT warrants — — 63,000 63,000 a. Valuation Processes-Level 3 third third The assumptions used in the Monte Carlo simulation as of September 30, 2017 December 31, 2016 September 30, 2017 December 31, 2016 Estimated volatility 0 % 76 % Expected term (in years) 0 4.75 Debt rate 8.125 % 8.125 % Beginning stock price $ 0.42 $ 0.64 b. Sensitivity Analysis-Level 3 Changes in the Company’s current internal estimates and forecasts were likely to cause material changes in the fair value of the Platinum conversion option. The significant unobservable inputs used in the fair value measurement of the liability included the amount and timing of future draws expected to be taken under the Platinum Loan Agreement based on then-current internal forecasts and management’s estimate of the likelihood of actually making those draws as opposed to obtaining other sources of financing. Significant increases (decreases) in any of the significant unobservable inputs would result in a higher (lower) fair value measurement. A change in one not There were no 1 or Level 2 three nine September 30, 2017 2016. no 1 2 three nine September 30, 2017 2016. 3 3 three September 30, 2017 2016 $0 $839,000, 3 nine September 30, 2017 2016 $153,000 $1.8

Note 5 - Stock-Based Compensati

Note 5 - Stock-Based Compensation	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	5 . Stock-Based Compensation For the three September 30, 2017 2016, $64,000 $50,000, nine September 30, 2017 2016, $320,000 $311,000, not three nine September 30, 2017 2016. A summary of the status of our stock options as of September 30, 2017, nine Nine Months Ended September 30 , 2017 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding at beginning of period 3,380,615 $ 2.00 Granted 1,390,000 0.75 Exercised — — Canceled and Forfeited (756,601 ) 1.64 Expired — — Outstanding at end of period 4,014,014 $ 1.63 6.6 $ 2,650 Exercisable at end of period 2,519,780 $ 2.11 4.9 $ 2,650 A summary of the status of our unvested restricted stock as of September 30, 2017, nine Nine Months Ended September 30 , 2017 Number of Shares Weighted Average Grant-Date Fair Value Unvested at beginning of period 207,000 $ 1.17 Granted 200,000 0.51 Vested (207,000 ) 1.17 Forfeited — — Unvested at end of period 200,000 $ 0.51 As of September 30, 2017, $181,000 1

Note 6 - Earnings (Loss) Per Sh

Note 6 - Earnings (Loss) Per Share	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Earnings Per Share [Text Block]	6 . Earnings (Loss) Per Share Basic earnings (loss) per share is calculated by dividing net income (loss) attributable to common stockholders by the weighted-average number of common shares and, except for periods with a loss from operations, participating securities outstanding during the period. Diluted earnings (loss) per share reflects additional common shares that would have been outstanding if dilutive potential common shares had been issued. Potential common shares that may The following table sets forth the reconciliation of the weighted average number of common shares outstanding used to compute basic and diluted earnings (loss) per share for the three nine September 30, 2017 2016: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Weighted average shares outstanding, basic 162,006,646 155,481,278 161,437,276 155,390,911 Dilutive shares related to warrants — — 4,277,197 — Unvested restricted stock — — 200,000 — Weighted average shares outstanding, diluted 162,006,646 155,481,278 165,914,473 155,390,911 Diluted earnings (loss) per common share for the nine September 30, 2017 2016 15.1 14.5 The Company ’s unvested stock awards contain nonforfeitable rights to dividends or dividend equivalents, whether paid or unpaid (referred to as “participating securities”). Therefore, the unvested stock awards are required to be included in the number of shares outstanding for both basic and diluted earnings per share calculations. However, due to our loss from continuing operations, 200,000 257,000 nine September 30, 2017 2016,

Note 7 - Inventory

Note 7 - Inventory	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Inventory Disclosure [Text Block]	7 . Inventory All components of inventory are valued at the lower of cost ( first first net realizable value. We adjust inventory to net realizable value if the net realizable value is lower than the carrying cost of the inventory. Net realizable value is determined based on estimated sales activity and margins. We estimate a reserve for obsolete inventory based on management’s judgment of probable future commercial use, which is based on an analysis of current inventory levels, estimated future sales and production rates, and estimated shelf lives. The components of inventory as of September 30, 2017 December 31, 2016 September 30 , 2017 December 31, 2016 (unaudited) Materials $ — $ 94,500 Work-in-process — 1,708 Finished goods 748 — Reserves (748 ) — Total $ — $ 96,208

Note 8 - Investment in Macropha

Note 8 - Investment in Macrophage Therapeutics, Inc.	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Investments in and Advances to Affiliates, Schedule of Investments [Text Block]	8 . Investment in Macrophage Therapeutics, Inc. In March 2015, Platinum and Dr. Goldberg (collectively, the “MT Investors”) invested $300,000 $200,000, In December 2015 May 2016, made additional investments in MT totaling $200,000 not December 31, 2016, $200,000 In 2016, ’s Board of Directors authorized modification of the original MT Preferred Stock to a convertible preferred stock with a 10% $500 first $200,000 December 2015 May 2016. $200,000 January 2017. 10 not

Note 9 - Accounts Payable, Accr

Note 9 - Accounts Payable, Accrued Liabilities and Other	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	9 . Accounts Payable , Accrued Liabilities and Other Accounts payable at September 30, 2017 December 31, 2016 $0 $116,000, September 30, 2017, $96,000 December 31, 2016. Accrued liabilities and other at September 30, 2017 $64,000 December 31, 2016 $106,000

Note 10 - Notes Payable

Note 10 - Notes Payable	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Debt Disclosure [Text Block]	10 . Notes Payable Platinum In July 2012, -Montaur to provide us with a credit facility of up to $50 414, $7.7 $1.9 not September 2017, not During the nine September 30, 2017 2016, $211,000 $814,000 September 30, 2017, $2.0 Until such time as there is a legal determination regarding liability under the Platinum Note, it is reflected as a liability on the consolidated balance sheets at its unpaid principal and interest balance of $1,981,676 $9,487,822 September 30, 2017 December 31, 2016, $0 $153,000 September 30, 2017 December 31, 2016, $0 $839,000, three September 30, 2017 2016. $153,000 $1.8 nine September 30, 2017 2016. Capital Royalty Partners II, L.P. In May 2015, “CRG Loan Agreement”) with Capital Royalty Partners II L.P. (“CRG”) in its capacity as a lender and as control agent for other affiliated lenders party to the CRG Loan Agreement (collectively, the “Lenders”) in which the Lenders agreed to make a term loan to the Company in the aggregate principal amount of $50 $10 three March 31, 2016, $519,000 Pursuant to a notice of default letter sent to Navidea by CRG in April 2016, second 2016 December 31, 2016, $5.8 December 31, 2016, $51.7 During the course of 2016, June 22, 2016, one ’s primary bank accounts and took possession of $4.1 On March 3, 2017, 414 February 22, 2017. March 3, 2017, $59 no no $47 no $66 414 posted a $7 $12 one 414 414 $59 first 414, 414 414 414 414, 414 IPFS Corporation In December 2016, $348,000 8.99%. was payable in eight $45,000, July 10, 2017. September 30, 2017 December 31, 2016, $0 $306,000, Summary During the three September 30, 2017 2016, $26,000 $2.6 $29,000 $190,000, three September 30, 2017 2016, nine September 30, 2017 2016, $1.8 $12.3 $0 $78,000, $211,000 $1.4 nine September 30, 2017 2016, $778,000, $2.1 $2.0 nine September 30, 2016.

Note 11 - Terminated Lease Liab

Note 11 - Terminated Lease Liability	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Terminated Lease Liability Disclosure [Text Block]	1 1 . Terminated Lease Liability Effective June 1, 2017, 5600 4995 no October 2022. In accordance with current accounting guidance, the Company recorded a total liability of $ 1.0 $429,000 $706,000. nine September 30, 2017. A summary of the changes in our terminated lease liability during the nine September 30, 2017 Terminated Lease Liability Total liability, June 1, 2017 (date of sublease) $ 943,675 Additional finder ’s fees required by contract 80,371 Payment of finder’s fees (152,584 ) Payments under Blazer lease (188,847 ) Receipts from subtenant 78,248 Accretion of liability 12,813 Total liability, September 30, 2017 $ 773,676

Note 12 - Commitments and Conti

Note 12 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	12. Commitments and Contingencies We are subject to legal proceedings and claims that arise in the ordinary course of business. Sinotau Litigation – NAV4694 On August 31, 2015, Sinotau”) filed a suit for damages, specific performance, and injunctive relief against the Company in the U.S. District Court for the District of Massachusetts alleging breach of a letter of intent for licensing to Sinotau of the Company’s NAV4694 September 2016, July 20, 2017, 60 October 26, 2017, NAV4694, NAV4694 not CRG Litigation During the course of 2016, June 22, 2016, one ’s primary bank accounts and took possession of $4.1 $3.9 $189,000 2016 2017. On March 3, 2017, 414 February 22, 2017. March 3, 2017, $59 no no $47 no $66 In addition, CRG agreed that Navidea had the right to assert all affirmative defenses to its claim of default. In the underlying case the district court had entered summary judgment in favor of CRG finding unspecified events of default but refusing to consider affirmative defenses raised by Navidea as not December 2017. October 30, 2017. not December 11, 2017. C oncurrently with the payment of the Deposit Amount and closing of the Asset Sale, (i) Cardinal Health 414 $7 414’s $12 one 414 414 $59 first 414, 414 414 414 414, 414 $2 $3 2 10. Former CEO Arbitration On May 12, 2016 ’s then Chief Executive Officer, claiming that he was terminated without cause and, alternatively, that he resigned in accordance with Section 4G May 9, 2016. May 13, 2016, May 12, 2017, April 7, 2016. $481,039 $617,880 May 16, 2017. FTI Consulting, Inc. Litigation On October 11, 2016, $782,600 $730,264 $52,337 ’ fees, costs and expenses. On November 14, 2016, February 7, 2017, June 26, 2017, June 2017, $862,165 $435,000 June 30, 2017. Sinotau Litigation – Tc99m On February 1, 2017, in the U.S. District Court for the Southern District of Ohio. The Company's complaint included claims seeking a declaration of the rights and obligations of the parties to an agreement regarding rights for the Tc99m 414. February 3, 2017, March 6, 2017. March 3, 2017. March 6, 414 February 2, 2017. July 12, 2017, July 27, 2017 60 not Platinum-Montaur Life Sciences LLC On November 2, 2017, $1,914,827 March 3, 2017, fter. The claims asserted are for breach of contract and unjust enrichment in connection with funds received by the Company under the Platinum Loan Agreement (discussed above). The Company has not In accordance with ASC Topic 450, Contingencies $7 not

Note 13 - Equity Instruments

Note 13 - Equity Instruments	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	1 3 . Equity Instruments During the nine September 30, 2017 2016, 16,406 72,649 $10,500 $56,609 Also during the nine September 30, 2017, 710,353 $369,342 2015 2016

Note 14 - Stock Warrants

Note 14 - Stock Warrants	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Stock Warrants Disclosure [Text Block]	1 4 . Stock Warrants In January 2017, ’s President and CEO, exercised 5,411,850 5,411,850 $54,119. In March 2017, the Company granted to each of Cardinal Health 414 five 10 1 $1.50 five 77% five 2%. 414 $3.3 three March 31, 2017. $334,000, three March 31, 2017. At September 30, 2017, 16.9 $0.01 $3.04 $1.19 1 18 In addition, at September 30, 2017, 300 $2,000

Note 15 - Income Taxes

Note 15 - Income Taxes	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Income Tax Disclosure [Text Block]	1 5 . Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Due to the uncertainty surrounding the realization of the deferred tax assets in future tax returns, all of the deferred tax assets have been fully offset by a valuation allowance at September 30, 2017 December 31, 2016. Current accounting standards include guidance on the accounting for uncertainty in income taxes recognized in the financial statements. Such standards also prescribe a recognition threshold and measurement model for the financial statement recognition of a tax position taken, or expected to be taken, and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company believes that the ultimate deductibility of all tax positions is highly certain, although there is uncertainty about the timing of such deductibility. As a result, no September 30, 2017 December 31, 2016 not twelve September 30, 2017, 2013 2016 Benefit from income taxes was $789,000 three September 30, 2017, 34%, $0 three September 30, 2016, 0%. September 30, 2017 2016 As of September 30, 2017, $127.7 $16.2

Note 16 - Segments

Note 16 - Segments	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	1 6 . Segments We report information about our operating segments using the “management approach” in accordance with current accounting standards. This information is based on the way management organizes and reports the segments within the enterprise for making operating decisions and assessing performance. Our reportable segments are identified based on differences in products, services and markets served. There were no two Tc99m May 31, 2016), NAV4694 NAV5001 April 2015), The information in the following tables is derived directly from each reportable segment ’s financial reporting. Three Months Ended September 30, 201 7 Diagnostics Therapeutics Corporate Total Tc99m tilmanocept sales revenue : United State s $ — $ — $ — $ — Internationa l — — — — Tc99m tilmanocept license revenu e — — — — Grant and other revenu e 210,479 13,190 — 223,669 Total revenu e 210,479 13,190 — 223,669 Cost of goods sold, excluding depreciation and amortizatio n — — — — Research and development expenses , excluding depreciation and amortization 734,539 140,008 — 874,547 Selling, general and administrative expenses , excluding depreciation and amortization (1) — 13,359 1,671,022 1,684,381 Depreciation and amortization (2 ) — — 50,326 50,326 Loss from operations (3 ) (524,060 ) (140,177 ) (1,721,348 ) (2,385,585 ) Other income (4 ) — — 69,071 69,071 Income tax benefi t 175,496 46,942 553,312 775,750 Net loss from continuing operation s (348,564 ) (93,235 ) (1,098,965 ) (1,540,764 ) Income from discontinued operations, net of ta x 5,399 — — 5,399 Gain on sale of discontinued operations, net of ta x 145,877 — — 145,877 Net los s (197,288 ) (93,235 ) (1,098,965 ) (1,389,488 ) Total assets, net of depreciation and amortization : United State s 14,675,489 10,591 7,835,426 22,521,506 Internationa l 82,334 — 1,867 84,201 Capital expenditures — — 23,247 23,247 Three Months Ended September 30 , 2016 Diagnostics Therapeutics Corporate Total Tc99m tilmanocept sales revenue: United States $ — $ — $ — $ — International 17,601 — — 17,601 Tc99m tilmanocept license revenue 1,295,625 — — 1,295,625 Grant and other revenue 500,628 10,346 — 510,974 Total revenue 1,813,854 10,346 — 1,824,200 Cost of goods sold, excluding depreciation and amortization 2,889 — — 2,889 Research and development expenses, excluding depreciation and amortization 671,777 247,664 — 919,441 Selling, general and administrative expenses, excluding depreciation and amortization ( 1 ) — 27,758 1,694,073 1,721,831 Depreciation and amortization ( 2 ) — — 89,849 89,849 Income (l oss) from operations ( 3 ) 1,139,188 (265,076 ) (1,783,922 ) (909,810 ) Other expenses ( 4 ) — — (851,637 ) (851,637 ) Net income (loss) from continuing operations 1,139,188 (265,076 ) (2,635,559 ) (1,761,447 ) Income from discontinued operations, net of tax 1,701,911 — — 1,701,911 Net income (loss) 2,841,099 (265,076 ) (2,635,559 ) (59,536 ) Total assets, net of depreciation and amortization: United States 4,950,756 9,356 6,080,567 11,040,679 International 148,224 — 697 148,921 Capital expenditures — — — — Nine Months Ended September 30, 2017 Diagnostics Therapeutics Corporate Total Tc99m tilmanocept sales revenue: United States $ — $ — $ — $ — International — — — — Tc99m tilmanocept license revenue 100,000 — — 100,000 Grant and other revenue 1,200,216 115,082 — 1,315,298 Total revenue 1,300,216 115,082 — 1,415,298 Cost of goods sold, excluding depreciation and amortization — — — — Research and development expenses, excluding depreciation and amortization 2,255,842 509,853 — 2,765,695 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 19,342 8,789,728 8,809,070 Depreciation and amortization (2) — — 197,655 197,655 L oss from operations (3) (955,626 ) (414,113 ) (8,987,383 ) (10,357,122 ) Other expenses (4) — — (1,061,190 ) (1,061,190 ) Income tax benefit 323,149 140,034 3,397,972 3,861,156 Net loss from continuing operations (632,477 ) (274,079 ) (6,650,601 ) (7,557,156 ) Loss from discontinued operations, net of tax (332,838 ) — — (332,838 ) Gain on sale of discontinued operations, net of tax 86,894,000 — — 86,894,000 Net income (loss) 85,928,685 (274,079 ) (6,650,601 ) 79,004,006 Total assets, net of depreciation and amortization: United States 14,675,489 10,591 7,835,426 22,521,506 International 82,334 — 1,867 84,201 Capital expenditures — — 31,417 31,417 Nine Months Ended September 30 , 2016 Diagnostics Therapeutics Corporate Total Tc99m tilmanocept sales revenue: United States $ — $ — $ — $ — International 30,800 — — 30,800 Tc99m tilmanocept license revenue 1,795,625 — — 1,795,625 Grant and other revenue 2,051,622 61,798 — 2,113,420 Total revenue 3,878,047 61,798 — 3,939,845 Cost of goods sold, excluding depreciation and amortization 5,185 — — 5,185 Research and development expenses, excluding depreciation and amortization 4,410,133 600,790 — 5,010,923 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 31,590 5,542,034 5,573,624 Depreciation and amortization (2) — — 258,999 258,999 Loss from operations (3) (537,271 ) (570,582 ) (5,801,033 ) (6,908,886 ) Other income, excluding equity in loss of R-NAV, LLC (4) — — 1,664,265 1,664,265 Equity in loss of R-NAV, LLC — — (15,159 ) (15,159 ) Net loss from continuing operations (537,271 ) (570,582 ) (4,151,927 ) (5,259,780 ) Loss from discontinued operations, net of tax (5,167,312 ) — — (5,167,312 ) Net loss (5,704,583 ) (570,582 ) (4,151,927 ) (10,427,092 ) Total assets, net of depreciation and amortization: United States 4,950,756 9,356 6,080,567 11,040,679 International 148,224 — 697 148,921 Capital expenditures — — 1,847 1,847 ( 1 General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not ( 2 ) Depreciation and amortization is reflected in selling, general and administrative expenses ( $50,326 $89,849 three September 30, 2017 2016 $197,655 $258,999 nine September 30, 2017 2016, ( 3 ) Income (loss) from operations does not ( 4 ) Amounts consist primarily of changes in fair value of financial instruments and losses on debt extinguishment, which are not

Note 17 - Supplemental Disclosu

Note 17 - Supplemental Disclosure for Statements of Cash Flows	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	1 7 . Supplemental Disclosure for Statements of Cash Flows During the nine September 30, 2017 2016, $7.4 $4.2 nine September 30, 2016 $778,000 $2.1 nine September 30, 2017, 1 $334,000. 8, $200,000 January 2017. nine September 30, 2017 2016, 105,308 67,002 401 $53,707 $120,800,

Note 18 - Subsequent Events

Note 18 - Subsequent Events	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Subsequent Events [Text Block]	1 8 . Subsequent Events The Company has evaluated events and transactions subsequent to September 30, 2017 10

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	a. Basis of Presentation: The information presented as of September 30, 2017 three nine September 30, 2017 2016 September 30, 2017 not December 31, 2016, 10 Our consolidated financial statements include the accounts of Navidea and our wholly owned subsidiaries, Navidea Biopharmaceuticals Limited and Cardiosonix Ltd, as well as those of our majority-owned subsidiary, Macrophage Therapeutics, Inc. ( “MT”). All significant inter-company accounts were eliminated in consolidation. Cardiosonix was legally dissolved in September 2017. May 2016, not On March 3, 2017, November 23, 2016, ( 414, 414” ’s radioactive diagnostic agent marketed under the Lymphoseek ® Upon closing of the Asset Sale, the Supply and Distribution Agreement, dated November 15, 2007 ( 414 no Our consolidated balance sheets and statements of operations have been reclassified, as required, for all periods presented to reflect the Business as a discontinued operation. Cash flows associated with the operation of the Business have been combined with operating, investing and financing cash flows, as appropriate, in our consolidated statement s of cash flows. See Note 3.
Fair Value of Financial Instruments, Policy [Policy Text Block]	b. Financial Instruments and Fair Value: In accordance with current accounting standards, the fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value, giving the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 3 three Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2 – Quoted prices in markets that are not Level 3 – Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. A financial instrument ’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. In determining the appropriate levels, we perform a detailed analysis of the assets and liabilities whose fair value is measured on a recurring basis. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no 3. 4. The following methods and assumptions were used to estimate the fair value of each class of financial instruments: ( 1 Cash, restricted cash, available-for-sale securities, accounts and other receivables, and accounts payable: The carrying amounts approximate fair value because of the short maturity of these instruments. ( 2 Notes payable: At September 30, 2017 December 31, 2016, 3 September 30, 2017, zero 10. ( 3 Derivative liabilities: Derivative liabilities are related to certain outstanding warrants which are recorded at fair value. Derivative liabilities totaling $63,000 September 30, 2017 December 31, 2016 September 30, 2017 December 31, 2016 4. ( 4 Warrants: In March 2017, 414 five 10 1 $1.50 414 $3.3 three March 31, 2017. $334,000, three March 31, 2017. 14.
Revenue Recognition, Policy [Policy Text Block]	c. Revenue Recognition: We currently generate revenue primarily from grants to support various product development initiatives. We generally recognize grant revenue when expenses reimbursable under the grants have been paid and payments under the grants become contractually due. We also earn revenues related to our licensing and distribution agreements. The terms of these agreements may not $2.0 March 2015. id not not not two $417,000 September 2016,
New Accounting Pronouncements, Policy [Policy Text Block]	d. Recent ly Adopted Accounting Standards : March 2016, No. 2016 09, Compensation – Stock Compensation (Topic 178 2016 09 2016 09 December 15, 2016, 2016 09 January 1, 2017 not ● As of December 31, 2016, $15.3 December 31, 2016, zero 2016 09. ● Due to the full valuation allowance for the Company’s tax provision, these APIC NOLs have never been recorded in additional paid-in-capital. The Company does not ● The Company will continue to recognize forfeitures through estimates consistent with our past practices as opposed to when they occur. ● The Company already classifies cash paid to taxing authorities arising from the withholding of shares from employees in cash flows from financing activities. e. Recent Accounting Standards: In May 2014, No. 2014 09, Revenue from Contracts with Customers (Topic 606 2014 09 2014 09 five may 2014 09, 606 2014 09 2014 09 2014 09 December 15, 2017, Following the sale of the Business to Cardinal Health 414 March 2017, we generate revenue primarily from grants to support certain of our product development programs. Such grant revenues are recognized only after expenses reimbursable under the grants have been paid. We also earn revenues related to our licensing and distribution agreements. The consideration we are eligible to receive under our licensing and distribution agreements typically includes upfront payments, reimbursement for research and development costs, milestone payments, and royalties. Each licensing and distribution agreement is unique and will require separate assessment using the five 2014 09. 2014 09, not 2014 09 January 1, 2018. In January 2017, No. 2017 01, 805 2017 01 not not not 2017 01 1 2 2017 01 December 15, 2017, 2017 01 No 2017 01. 2017 01 In May 2017, No. 2017 09, Compensation-Stock Compensation (Topic 718 2017 09 1 not not 2 3 2017 09 December 15, 2017. 2017 09. 2017 09 In September 2017, No. 2017 13, Revenue Recognition (Topic 605 606 840 842 2017 13 July 2017 2017 13

Note 3 - Discontinued Operati27

Note 3 - Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Disposal Groups, Including Discontinued Operations [Table Text Block]	September 30 , 2017 December 31, 2016 Accounts and other receivables $ — $ 1,598,994 Inventory, net — 1,374,618 Prepaid expenses — 170,635 Assets associated with discontinued operations, current — 3,144,247 Property and equipment, net of accumulated depreciation — 70,973 Patents and trademarks, net of accumulated amortization — 34,282 Assets associated with discontinued operations, noncurrent — 105,255 Total a ssets associated with discontinued operations $ — $ 3,249,502 Accounts payable $ 232 $ 1,957,938 Accrued liabilities 32,909 607,659 Deferred revenue — 2,300,000 Liabilities associated with discontinued operations, current $ 33,141 $ 4,865,597 Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Revenue: Lymphoseek sales revenue $ — $ 6,672,489 $ 2,917,213 $ 14,673,689 Grant and other revenue — 385 — 575 Total revenue — 6,672,874 2,917,213 14,674,264 Cost of goods sold — 918,928 364,192 2,012,301 Gross profit — 5,753,946 2,553,021 12,661,963 Operating expenses: Research and development (5,951 ) 356,612 382,070 1,450,231 Selling, general and administrative — 1,129,093 805,464 4,092,951 Total operating expenses (5,951 ) 1,485,705 1,187,534 5,543,182 Income from discontinued operations 5,951 4,268,241 1,365,487 7,118,781 Interest expense — (2,566,330 ) (1,718,506 ) (12,286,093 ) Income (l oss) before income taxes 5,951 1,701,911 (353,019 ) (5,167,312 ) Benefit from (provision for) income taxes (552 ) — 20,181 — Income (l oss) from discontinued operations $ 5,399 $ 1,701,911 $ (332,838 ) $ (5,167,312 )

Note 4 - Fair Value (Tables)

Note 4 - Fair Value (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	Liabilities Measured at Fair Value on a Recurri ng Basis as of September 30, 2017 Description Quoted Prices in Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Platinum conversion option $ — $ — $ — $ — Liability related to MT warrants — — 63,000 63,000 Liabilities Measured at Fair Value on a Recurri ng Basis as of December 31, 2016 Description Quoted Prices in Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Platinum conversion option $ — $ — $ 153,357 $ 153,357 Liability related to MT warrants — — 63,000 63,000
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	September 30, 2017 December 31, 2016 Estimated volatility 0 % 76 % Expected term (in years) 0 4.75 Debt rate 8.125 % 8.125 % Beginning stock price $ 0.42 $ 0.64

Note 5 - Stock-Based Compensa29

Note 5 - Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Nine Months Ended September 30 , 2017 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding at beginning of period 3,380,615 $ 2.00 Granted 1,390,000 0.75 Exercised — — Canceled and Forfeited (756,601 ) 1.64 Expired — — Outstanding at end of period 4,014,014 $ 1.63 6.6 $ 2,650 Exercisable at end of period 2,519,780 $ 2.11 4.9 $ 2,650
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Nine Months Ended September 30 , 2017 Number of Shares Weighted Average Grant-Date Fair Value Unvested at beginning of period 207,000 $ 1.17 Granted 200,000 0.51 Vested (207,000 ) 1.17 Forfeited — — Unvested at end of period 200,000 $ 0.51

Note 6 - Earnings (Loss) Per 30

Note 6 - Earnings (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Weighted average shares outstanding, basic 162,006,646 155,481,278 161,437,276 155,390,911 Dilutive shares related to warrants — — 4,277,197 — Unvested restricted stock — — 200,000 — Weighted average shares outstanding, diluted 162,006,646 155,481,278 165,914,473 155,390,911

Note 7 - Inventory (Tables)

Note 7 - Inventory (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30 , 2017 December 31, 2016 (unaudited) Materials $ — $ 94,500 Work-in-process — 1,708 Finished goods 748 — Reserves (748 ) — Total $ — $ 96,208

Note 11 - Terminated Lease Li32

Note 11 - Terminated Lease Liability (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Terminated Lease Liability [Table Text Block]	Terminated Lease Liability Total liability, June 1, 2017 (date of sublease) $ 943,675 Additional finder ’s fees required by contract 80,371 Payment of finder’s fees (152,584 ) Payments under Blazer lease (188,847 ) Receipts from subtenant 78,248 Accretion of liability 12,813 Total liability, September 30, 2017 $ 773,676

Note 16 - Segments (Tables)

Note 16 - Segments (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended September 30, 201 7 Diagnostics Therapeutics Corporate Total Tc99m tilmanocept sales revenue : United State s $ — $ — $ — $ — Internationa l — — — — Tc99m tilmanocept license revenu e — — — — Grant and other revenu e 210,479 13,190 — 223,669 Total revenu e 210,479 13,190 — 223,669 Cost of goods sold, excluding depreciation and amortizatio n — — — — Research and development expenses , excluding depreciation and amortization 734,539 140,008 — 874,547 Selling, general and administrative expenses , excluding depreciation and amortization (1) — 13,359 1,671,022 1,684,381 Depreciation and amortization (2 ) — — 50,326 50,326 Loss from operations (3 ) (524,060 ) (140,177 ) (1,721,348 ) (2,385,585 ) Other income (4 ) — — 69,071 69,071 Income tax benefi t 175,496 46,942 553,312 775,750 Net loss from continuing operation s (348,564 ) (93,235 ) (1,098,965 ) (1,540,764 ) Income from discontinued operations, net of ta x 5,399 — — 5,399 Gain on sale of discontinued operations, net of ta x 145,877 — — 145,877 Net los s (197,288 ) (93,235 ) (1,098,965 ) (1,389,488 ) Total assets, net of depreciation and amortization : United State s 14,675,489 10,591 7,835,426 22,521,506 Internationa l 82,334 — 1,867 84,201 Capital expenditures — — 23,247 23,247 Three Months Ended September 30 , 2016 Diagnostics Therapeutics Corporate Total Tc99m tilmanocept sales revenue: United States $ — $ — $ — $ — International 17,601 — — 17,601 Tc99m tilmanocept license revenue 1,295,625 — — 1,295,625 Grant and other revenue 500,628 10,346 — 510,974 Total revenue 1,813,854 10,346 — 1,824,200 Cost of goods sold, excluding depreciation and amortization 2,889 — — 2,889 Research and development expenses, excluding depreciation and amortization 671,777 247,664 — 919,441 Selling, general and administrative expenses, excluding depreciation and amortization ( 1 ) — 27,758 1,694,073 1,721,831 Depreciation and amortization ( 2 ) — — 89,849 89,849 Income (l oss) from operations ( 3 ) 1,139,188 (265,076 ) (1,783,922 ) (909,810 ) Other expenses ( 4 ) — — (851,637 ) (851,637 ) Net income (loss) from continuing operations 1,139,188 (265,076 ) (2,635,559 ) (1,761,447 ) Income from discontinued operations, net of tax 1,701,911 — — 1,701,911 Net income (loss) 2,841,099 (265,076 ) (2,635,559 ) (59,536 ) Total assets, net of depreciation and amortization: United States 4,950,756 9,356 6,080,567 11,040,679 International 148,224 — 697 148,921 Capital expenditures — — — — Nine Months Ended September 30, 2017 Diagnostics Therapeutics Corporate Total Tc99m tilmanocept sales revenue: United States $ — $ — $ — $ — International — — — — Tc99m tilmanocept license revenue 100,000 — — 100,000 Grant and other revenue 1,200,216 115,082 — 1,315,298 Total revenue 1,300,216 115,082 — 1,415,298 Cost of goods sold, excluding depreciation and amortization — — — — Research and development expenses, excluding depreciation and amortization 2,255,842 509,853 — 2,765,695 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 19,342 8,789,728 8,809,070 Depreciation and amortization (2) — — 197,655 197,655 L oss from operations (3) (955,626 ) (414,113 ) (8,987,383 ) (10,357,122 ) Other expenses (4) — — (1,061,190 ) (1,061,190 ) Income tax benefit 323,149 140,034 3,397,972 3,861,156 Net loss from continuing operations (632,477 ) (274,079 ) (6,650,601 ) (7,557,156 ) Loss from discontinued operations, net of tax (332,838 ) — — (332,838 ) Gain on sale of discontinued operations, net of tax 86,894,000 — — 86,894,000 Net income (loss) 85,928,685 (274,079 ) (6,650,601 ) 79,004,006 Total assets, net of depreciation and amortization: United States 14,675,489 10,591 7,835,426 22,521,506 International 82,334 — 1,867 84,201 Capital expenditures — — 31,417 31,417 Nine Months Ended September 30 , 2016 Diagnostics Therapeutics Corporate Total Tc99m tilmanocept sales revenue: United States $ — $ — $ — $ — International 30,800 — — 30,800 Tc99m tilmanocept license revenue 1,795,625 — — 1,795,625 Grant and other revenue 2,051,622 61,798 — 2,113,420 Total revenue 3,878,047 61,798 — 3,939,845 Cost of goods sold, excluding depreciation and amortization 5,185 — — 5,185 Research and development expenses, excluding depreciation and amortization 4,410,133 600,790 — 5,010,923 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 31,590 5,542,034 5,573,624 Depreciation and amortization (2) — — 258,999 258,999 Loss from operations (3) (537,271 ) (570,582 ) (5,801,033 ) (6,908,886 ) Other income, excluding equity in loss of R-NAV, LLC (4) — — 1,664,265 1,664,265 Equity in loss of R-NAV, LLC — — (15,159 ) (15,159 ) Net loss from continuing operations (537,271 ) (570,582 ) (4,151,927 ) (5,259,780 ) Loss from discontinued operations, net of tax (5,167,312 ) — — (5,167,312 ) Net loss (5,704,583 ) (570,582 ) (4,151,927 ) (10,427,092 ) Total assets, net of depreciation and amortization: United States 4,950,756 9,356 6,080,567 11,040,679 International 148,224 — 697 148,921 Capital expenditures — — 1,847 1,847

Note 1 - Summary of Significa34

Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	1 Months Ended			3 Months Ended	9 Months Ended
	Mar. 31, 2017	Sep. 30, 2016	Mar. 31, 2015	Mar. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
Derivative Liability					$ 63,000	$ 63,000
Notes Payable, Fair Value Disclosure					$ 0
Accounting Standards Update 2016-09 [Member]
Operating Loss Carryforwards						$ 15,300,000
Nonsoftware License Arrangement [Member] | SpePharm AG [Member]
Deferred Revenue, Additions			$ 2,000,000
Deferred Revenue, Recognition Period			2 years
Deferred Revenue, Revenue Recognized		$ 417,000
Series NN Warrants [Member]
Class of Warrant or Right, Term	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.50			$ 1.50
Series NN Warrants [Member] | Cardinal Health 414 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	10,000,000			10,000,000
Class of Warrant or Right, Grants in Period, Estimated Fair Value				$ 3,300,000
Series NN Warrants [Member] | UCSD [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,000,000			1,000,000	1,000,000
Class of Warrant or Right, Grants in Period, Estimated Fair Value				$ 334,000	$ 334,000

Note 2 - Liquidity (Details Tex

Note 2 - Liquidity (Details Textual) - USD ($) $ in Millions	Mar. 03, 2017	Jun. 22, 2016	Sep. 30, 2017	Feb. 28, 2017
CRG Loan Agreement, Ohio Case [Member]
Release of Cash Held in Escrow	$ 2
CRG Loan Agreement, Texas Case [Member]
Release of Cash Held in Escrow	3
Term Loan Agreement [Member] | Cardinal Health 414 [Member]
Letters of Credit Outstanding, Amount	7
Term Loan Agreement [Member] | CRG [Member]
Letters of Credit Outstanding, Amount	12
CRG [Member] | Term Loan Agreement [Member]
Debt Instrument, Interest Rate, Stated Percentage				14.00%
Debt Instrument, Default, Interest Rate, Stated Percentage				18.00%
Primary Bank Account Cash Taken Possession Of By Creditor		$ 4.1
Repayments of Debt	59
Debt Instrument, Final Payoff Amount, Threshold Above Which the Reporting Entity Will First Pay Without Resorting to Letter of Credit	59
Debt Instrument, Amount That May Become Due Depending on the Outcome of Litigation			$ 7
CRG [Member] | Term Loan Agreement [Member] | Minimum [Member]
Debt Instrument, Agreed-upon Final Payoff Amount	47
CRG [Member] | Term Loan Agreement [Member] | Maximum [Member]
Debt Instrument, Agreed-upon Final Payoff Amount	66
PPCO [Member] | Platinum Loan Agreement [Member]
Repayments of Debt	7.7
Convertible Debt	$ 1.9

Note 3 - Discontinued Operati36

Note 3 - Discontinued Operations (Details Textual) - USD ($)	Mar. 03, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax		$ 145,877		$ 86,894,000
Warrants Issued During Period, Value Issued, Asset Sale				3,337,187
Sale of Assets to Cardinal Health 414 [Member]
Sale of Assets, Cash Received from Buyer, After Adjustments, Inventory Transferred	$ 80,600,000
Sale of Assets, Cash Received from Buyer, After Adjustments, Advances of Guaranteed Earnout Payments	3,000,000
Purchase Agreement, Maximum Earnout Payments	$ 230,000,000
Purchase Agreement, Earnout Payments, Term	10 years
Purchase Agreement, Earnout Payments, Guaranteed	$ 20,100,000
Purchase Agreement, Earnout Payments, Guaranteed, Year One	6,700,000
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax				86,900,000
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Guaranteed Consideration				16,500,000
Warrants Issued During Period, Value Issued, Asset Sale				3,300,000
Sale of Assets, Legal and Other Fees Related to the Sale				2,000,000
Sale of Assets, Net Balance Sheet Dispositions and Write-offs		$ 800,000		800,000
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation				$ 6,400,000
Purchase Agreement, Earnout Payments, Guaranteed, Year Three	6,700,000
Purchase Agreement, Earnout Payments, Guaranteed, Year Two	$ 6,700,000

Note 3 - Discontinued Operati37

Note 3 - Discontinued Operations - Discontinued Operations (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Accounts and other receivables					$ 1,598,994
Inventory, net					1,374,618
Prepaid expenses					170,635
Assets associated with discontinued operations, current					3,144,247
Property and equipment, net of accumulated depreciation					70,973
Patents and trademarks, net of accumulated amortization					34,282
Assets associated with discontinued operations, noncurrent					105,255
Total assets associated with discontinued operations					3,249,502
Accounts payable	232		232		1,957,938
Accrued liabilities	32,909		32,909		607,659
Deferred revenue					2,300,000
Liabilities associated with discontinued operations, current	33,141		33,141		$ 4,865,597
Lymphoseek sales revenue		$ 6,672,489	2,917,213	$ 14,673,689
Grant and other revenue		385		575
Total revenue		6,672,874	2,917,213	14,674,264
Cost of goods sold		918,928	364,192	2,012,301
Gross profit		5,753,946	2,553,021	12,661,963
Research and development	(5,951)	356,612	382,070	1,450,231
Selling, general and administrative		1,129,093	805,464	4,092,951
Total operating expenses	(5,951)	1,485,705	1,187,534	5,543,182
Income from discontinued operations	5,951	4,268,241	1,365,487	7,118,781
Interest expense		(2,566,330)	(1,718,506)	(12,286,093)
Income (loss) before income taxes	5,951	1,701,911	(353,019)	(5,167,312)
Benefit from (provision for) income taxes	(552)		20,181
Income (loss) from discontinued operations	$ 5,399	$ 1,701,911	$ (332,838)	$ (5,167,312)

Note 4 - Fair Value (Details Te

Note 4 - Fair Value (Details Textual) - USD ($)	3 Months Ended		6 Months Ended	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Jun. 30, 2017	Sep. 30, 2017	Sep. 30, 2016	Mar. 03, 2017	Dec. 31, 2016
Derivative Liability	$ 63,000			$ 63,000			$ 63,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)					$ (1,800,000)
Fair Value, Inputs, Level 1 [Member]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0	$ 0		0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)	0	839,000	$ (153,000)
Fair Value, Inputs, Level 2 [Member]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0	0		0	0
PPCO [Member] | Platinum Loan Agreement [Member]
Convertible Debt						$ 1,900,000
Convertible Debt, Fair Value Disclosures	0			0			$ 153,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)	$ 0	$ 839,000		$ (153,000)	$ (1,800,000)

Note 4 - Fair Value - Financial

Note 4 - Fair Value - Financial Liabilities Measured At Fair Value On a Recurring Basis (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Derivative Liability	$ 63,000	$ 63,000
PPCO [Member] | Platinum Loan Agreement [Member]
Convertible Debt, Fair Value Disclosures	0	153,000
Fair Value, Measurements, Recurring [Member]
Derivative Liability	63,000	63,000
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Derivative Liability
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Derivative Liability
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Derivative Liability	63,000	63,000
Fair Value, Measurements, Recurring [Member] | PPCO [Member] | Platinum Loan Agreement [Member]
Convertible Debt, Fair Value Disclosures		153,357
Fair Value, Measurements, Recurring [Member] | PPCO [Member] | Fair Value, Inputs, Level 1 [Member] | Platinum Loan Agreement [Member]
Convertible Debt, Fair Value Disclosures
Fair Value, Measurements, Recurring [Member] | PPCO [Member] | Fair Value, Inputs, Level 2 [Member] | Platinum Loan Agreement [Member]
Convertible Debt, Fair Value Disclosures
Fair Value, Measurements, Recurring [Member] | PPCO [Member] | Fair Value, Inputs, Level 3 [Member] | Platinum Loan Agreement [Member]
Convertible Debt, Fair Value Disclosures		$ 153,357

Note 4 - Fair Value - Assumptio

Note 4 - Fair Value - Assumptions Used (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Estimated volatility	0.00%	76.00%
Expected term (Year)	0 years	4 years 273 days
Debt rate	8.125%	8.125%
Beginning stock price (in dollars per share)	$ 0.42	$ 0.64

Note 5 - Stock-Based Compensa41

Note 5 - Stock-Based Compensation (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Allocated Share-based Compensation Expense	$ 64,000	$ 50,000	$ 320,000	$ 311,000
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense	0	$ 0	0	$ 0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 181,000		$ 181,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			1 year

Note 5 - Stock-based Compensa42

Note 5 - Stock-based Compensation - Summary of Stock Option Activity (Details)	9 Months Ended
	Sep. 30, 2017USD ($)$ / sharesshares
Outstanding at beginning of period (in shares) | shares	3,380,615
Outstanding at beginning of period, weighted average exercise price (in dollars per share) | $ / shares	$ 2
Granted (in shares) | shares	1,390,000
Granted, weighted average exercise price (in dollars per share) | $ / shares	$ 0.75
Exercised (in shares) | shares
Exercised, weighted average exercise price (in dollars per share) | $ / shares
Canceled and Forfeited (in shares) | shares	(756,601)
Canceled and Forfeited, weighted average exercise price (in dollars per share) | $ / shares	$ 1.64
Expired (in shares) | shares
Expired, weighted average exercise price (in dollars per share) | $ / shares
Outstanding at end of period (in shares) | shares	4,014,014
Outstanding at end of period, weighted average exercise price (in dollars per share) | $ / shares	$ 1.63
Outstanding at end of period, weighted average remaining contractual life (Year)	6 years 219 days
Outstanding at end of period | $	$ 2,650
Exercisable at end of period (in shares) | shares	2,519,780
Exercisable at end of period, weighted average exercise price (in dollars per share) | $ / shares	$ 2.11
Exercisable at end of period, weighted average remaining contractual life (Year)	4 years 328 days
Exercisable at end of period | $	$ 2,650

Note 5 - Stock-based Compensa43

Note 5 - Stock-based Compensation - Summary of Unvested Restricted Stock (Details) - Restricted Stock [Member]	9 Months Ended
	Sep. 30, 2017$ / sharesshares
Unvested at beginning of period (in shares) | shares	207,000
Unvested at beginning of period, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 1.17
Granted (in shares) | shares	200,000
Granted, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 0.51
Vested (in shares) | shares	(207,000)
Vested, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 1.17
Forfeited (in shares) | shares
Forfeited, weighted average grant-date fair value (in dollars per share) | $ / shares
Unvested at end of period (in shares) | shares	200,000
Unvested at end of period, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 0.51

Note 6 - Earnings (Loss) Per 44

Note 6 - Earnings (Loss) Per Share (Details Textual) - shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Stock Options, Warrants, Convertible Debt, and Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	15,100,000	14,500,000
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	200,000	257,000

Note 6 - Earnings (Loss) Per 45

Note 6 - Earnings (Loss) Per Share - Earnings (Loss) Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Weighted average shares outstanding (basic) (in shares)	162,006,646	155,481,278	161,437,276	155,390,911
Dilutive shares related to warrants (in shares)			4,277,197
Unvested restricted stock (in shares)			200,000
Weighted average shares outstanding, diluted (in shares)	162,006,646	155,481,278	165,914,473	155,390,911

Note 7 - Inventory - Components

Note 7 - Inventory - Components of Inventory (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Materials		$ 94,500
Work-in-process		1,708
Finished goods	748
Reserves	(748)
Total		$ 96,208

Note 8 - Investment in Macrop47

Note 8 - Investment in Macrophage Therapeutics, Inc. (Details Textual) - USD ($)	1 Months Ended				9 Months Ended
	Jan. 31, 2017	May 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Sep. 30, 2017
Reclassification of Funds Invested	$ 200,000				$ 200,000
MT [Member]
Convertible Preferred Stock, PIK Coupon, Percentage		10.00%
Convertible Preferred Stock, Conversion Price, Market Cap		$ 500,000,000
MT [Member] | Chief Executive Officer [Member]
Payments to Acquire Businesses and Interest in Affiliates				$ 200,000
MT [Member] | Platinum [Member]
Payments to Acquire Businesses and Interest in Affiliates		$ 200,000	$ 200,000	$ 300,000

Note 9 - Accounts Payable, Ac48

Note 9 - Accounts Payable, Accrued Liabilities and Other (Details Textual) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Accounts Payable, Portion Under Dispute	$ 96,000
Accounts Payable [Member] | Director Fees and Scientific Advisory Board Fees [Member]
Due to Related Parties, Current	0	$ 116,000
Accrued Liabilities and Other [Member] | Executive Bonuses, Director Fees, Deferred Salary, and Scientific Advisory Board Fees [Member]
Due to Related Parties, Current	$ 64,000	$ 106,000

Note 10 - Notes Payable (Detail

Note 10 - Notes Payable (Details Textual) - USD ($)	Mar. 03, 2017	Jun. 22, 2016	Dec. 31, 2016	Sep. 30, 2017	Sep. 30, 2016	Mar. 31, 2016	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Feb. 28, 2017	May 31, 2015	Jul. 31, 2012
Paid-in-Kind Interest								$ 211,443	$ 1,367,259
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)									(1,800,000)
Interest Expense, Debt				$ 26,000	$ 2,600,000			1,800,000	12,300,000
Amortization of Debt Discount (Premium)				29,000	190,000			0	78,000
Term Loan Agreement [Member] | Cardinal Health 414 [Member]
Letters of Credit Outstanding, Amount	$ 7,000,000
Term Loan Agreement [Member] | CRG [Member]
Letters of Credit Outstanding, Amount	12,000,000
Notes Payable Issued for Prepayment of Insurance Premiums [Member] | IPFS [Member]
Notes Payable			$ 306,000	0				0
Debt Instrument, Face Amount			$ 348,000
Debt Instrument, Interest Rate, Stated Percentage			8.99%
Debt Instrument, Term			240 days
Debt Instrument, Periodic Payment			$ 45,000
Capital Royalty Group, Term Loan [Member]
Payments to Collection of Collateral on Claims of Default							$ 778,000		778,000
Payments to Prepayment Premium on Claims of Default							2,100,000		2,100,000
Debt Instrument, Unamortized Discount					2,000,000		$ 2,000,000		2,000,000
PPCO [Member] | Platinum Loan Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity												$ 50,000,000
Repayments of Debt	7,700,000
Convertible Debt	1,900,000
Paid-in-Kind Interest								211,000	814,000
Notes Payable			9,487,822	1,981,676				1,981,676
Embedded Derivative, Fair Value of Embedded Derivative Liability			153,000	0				0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)				$ 0	$ 839,000			$ (153,000)	$ (1,800,000)
CRG [Member] | Term Loan Agreement [Member]
Repayments of Debt	59,000,000
Paid-in-Kind Interest						$ 519,000
Notes Payable			51,700,000
Debt Instrument, Face Amount											$ 50,000,000
Debt Instrument, Additional Loans That May Be Made Available Upon the Satisfaction of Certain Conditions											$ 10,000,000
Primary Bank Account Cash Taken Possession Of By Creditor		$ 4,100,000
Debt Instrument, Final Payoff Amount, Threshold Above Which the Reporting Entity Will First Pay Without Resorting to Letter of Credit	59,000,000
Debt Instrument, Interest Rate, Stated Percentage										14.00%
CRG [Member] | Term Loan Agreement [Member] | Minimum [Member]
Debt Instrument, Agreed-upon Final Payoff Amount	47,000,000
CRG [Member] | Term Loan Agreement [Member] | Maximum [Member]
Debt Instrument, Agreed-upon Final Payoff Amount	$ 66,000,000
CRG [Member] | Term Loan Agreement [Member] | Accrued Liabilities and Other [Member]
Interest Payable, Current			$ 5,800,000

Note 11 - Terminated Lease Li50

Note 11 - Terminated Lease Liability (Details Textual) - Lease Termination of Blazer [Member] - USD ($)	9 Months Ended
	Sep. 30, 2017	Jun. 01, 2017	May 31, 2017
Terminated Lease Liability	$ 773,676	$ 1,000,000	$ 943,675
Selling, General and Administrative Expenses [Member]
Gain (Loss) on Contract Termination	429,000
Gain (Loss) on Disposition of Assets	$ (706,000)

Note 11 - Terminated Lease Li51

Note 11 - Terminated Lease Liability - Summary of Changes in Terminated Lease Liability (Details) - Lease Termination of Blazer [Member]	4 Months Ended
	Sep. 30, 2017USD ($)
Total liability, June 1, 2017 (date of sublease)	$ 943,675
Additional finder’s fees required by contract	80,371
Payment of finder’s fees	(152,584)
Payments under Blazer lease	(188,847)
Receipts from subtenant	78,248
Accretion of liability	12,813
Total liability, September 30, 2017	$ 773,676

Note 12 - Commitments and Con52

Note 12 - Commitments and Contingencies (Details Textual) - USD ($)	Nov. 02, 2017	May 16, 2017	May 12, 2017	Mar. 03, 2017	Oct. 11, 2016	Jun. 22, 2016	Jun. 30, 2017	Sep. 30, 2017
CRG Loan Agreement, Ohio Case [Member]
Release of Cash Held in Escrow				$ 2,000,000
CRG Loan Agreement, Texas Case [Member]
Release of Cash Held in Escrow				3,000,000
Former CEO Arbitration [Member]
Litigation Settlement, Salary, Bonus, and Benefits, Amount Awarded to Other Party			$ 481,039
Litigation Settlement, Amount Awarded to Other Party		$ 617,880
FTI Consulting, Inc. Litigation [Member] | Pending Litigation [Member] | Investigative and Consulting Services [Member]
Litigation Settlement, Amount Awarded to Other Party							$ 435,000
Loss Contingency, Damages Sought, Value					$ 730,264		$ 862,165
Platinum-Montaur Life Sciences LLC Litigation [Member] | Pending Litigation [Member] | Subsequent Event [Member]
Loss Contingency, Damages Sought, Value	$ 1,914,827
Minimum [Member] | FTI Consulting, Inc. Litigation [Member] | Pending Litigation [Member]
Loss Contingency, Damages Sought, Value					782,600
Minimum [Member] | FTI Consulting, Inc. Litigation [Member] | Pending Litigation [Member] | Purported Interest Due on Unpaid Invoices, Plus Attorneys' Fees, Costs and Expenses [Member]
Loss Contingency, Damages Sought, Value					$ 52,337
Maximum [Member] | Sinotau Litigation [Member] | Pending Litigation [Member]
Loss Contingency, Estimate of Possible Loss								$ 7,000,000
Term Loan Agreement [Member] | Cardinal Health 414 [Member]
Letters of Credit Outstanding, Amount				7,000,000
Term Loan Agreement [Member] | CRG [Member]
Letters of Credit Outstanding, Amount				12,000,000
CRG [Member] | Term Loan Agreement [Member]
Primary Bank Account Cash Taken Possession Of By Creditor						$ 4,100,000
Primary Bank Account Cash Taken Possession Of By Creditor, Portion Applied to Fees						3,900,000
Primary Bank Account Cash Taken Possession Of By Creditor, Portion Applied to the Principal Balance of Debt						$ 189,000
Repayments of Debt				59,000,000
Debt Instrument, Final Payoff Amount, Threshold Above Which the Reporting Entity Will First Pay Without Resorting to Letter of Credit				59,000,000
CRG [Member] | Term Loan Agreement [Member] | Minimum [Member]
Debt Instrument, Agreed-upon Final Payoff Amount				47,000,000
CRG [Member] | Term Loan Agreement [Member] | Maximum [Member]
Debt Instrument, Agreed-upon Final Payoff Amount				$ 66,000,000

Note 13 - Equity Instruments (D

Note 13 - Equity Instruments (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Stock Issued During Period, Value, Issued for Services	$ 10,500
Common Stock [Member]
Stock Issued During Period, Shares, Issued for Services	16,406
Stock Issued During Period, Value, Issued for Services	$ 17
Director [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Services	16,406	72,649
Stock Issued During Period, Value, Issued for Services	$ 10,500	$ 56,609
Employees [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Services	710,353
Stock Issued During Period, Value, Issued for Services	$ 369,342

Note 14 - Stock Warrants (Detai

Note 14 - Stock Warrants (Details Textual) - USD ($)	1 Months Ended		3 Months Ended	9 Months Ended
	Mar. 31, 2017	Jan. 31, 2017	Mar. 31, 2017	Sep. 30, 2017
Series NN Warrants [Member]
Class of Warrant or Right, Term	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.50		$ 1.50
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	77.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	2.00%
Series NN Warrants [Member] | Cardinal Health 414 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	10,000,000		10,000,000
Class of Warrant or Right, Grants in Period, Estimated Fair Value			$ 3,300,000
Series NN Warrants [Member] | UCSD [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,000,000		1,000,000	1,000,000
Class of Warrant or Right, Grants in Period, Estimated Fair Value			$ 334,000	$ 334,000
Warrants to Purchase Navidea Common Stock [Member]
Class of Warrant or Right, Outstanding				16,900,000
Warrants to Purchase Navidea Common Stock [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.01
Class of Warrant or Right, Outstanding Term				1 year
Warrants to Purchase Navidea Common Stock [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 3.04
Class of Warrant or Right, Outstanding Term				18 years
Warrants to Purchase Navidea Common Stock [Member] | Weighted Average [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 1.19
Warrants to Purchase MT Common Stock [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 2,000
Class of Warrant or Right, Outstanding				300
Chief Executive Officer [Member]
Class of Warrant or Right, Exercises in Period		5,411,850
Stock Issued During Period, Shares, Issued for Exercise of Warrants		5,411,850
Proceeds from Warrant Exercises		$ 54,119

Note 15 - Income Taxes (Details

Note 15 - Income Taxes (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Unrecognized Tax Benefits	$ 0		$ 0		$ 0
Income Tax Expense (Benefit)	$ (775,750)	$ 0	(3,861,156)
Effective Income Tax Rate Reconciliation, Percent	34.00%	0.00%
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards	$ 127,700,000		127,700,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	$ 16,200,000		$ 16,200,000

Note 16 - Segments (Details Tex

Note 16 - Segments (Details Textual)		3 Months Ended		9 Months Ended
		Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)
Revenues		$ 223,669	$ 1,824,200	$ 1,415,298	$ 3,939,845
Number of Primary Types of Products Sold		2		2
Depreciation, Depletion and Amortization, Nonproduction	[1]	$ 50,326	$ 89,849	$ 197,655	$ 258,999
Intersegment Eliminations [Member]
Revenues				$ 0
[1]	Depreciation and amortization is reflected in selling, general and administrative expenses ($50,326 and $89,849 for the three-month periods ended September 30, 2017 and 2016 and $197,655 and $258,999 for the nine-month periods ended September 30, 2017 and 2016, respectively).

Note 16 - Segments - Segment In

Note 16 - Segments - Segment Information (Details) - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Tc 99m tilmanocept sales revenue			$ 17,601		$ 30,800
Tc99m tilmanocept license revenue			1,295,625	100,000	1,795,625
Grant and other revenue		223,669	510,974	1,315,298	2,113,420
Revenues		223,669	1,824,200	1,415,298	3,939,845
Cost of goods sold, excluding depreciation and amortization			2,889		5,185
Research and development expenses, excluding depreciation and amortization		874,547	919,441	2,765,695	5,010,923
Selling, general and administrative expenses, excluding depreciation and amortization (1)	[1]	1,684,381	1,721,831	8,809,070	5,573,624
Depreciation, Depletion and Amortization, Nonproduction	[2]	50,326	89,849	197,655	258,999
Loss from operations (3)	[3]	(2,385,585)	(909,810)	(10,357,122)	(6,908,886)
Other income (4)		69,071	(851,637)	(1,061,190)	1,649,106
Income tax benefit		775,750	0	3,861,156
Net loss from continuing operations		(1,540,764)	(1,761,447)	(7,557,156)	(5,259,780)
Income from discontinued operations, net of tax		5,399	1,701,911	(332,838)	(5,167,312)
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax		145,877		86,894,000
Net income		(1,389,488)	(59,536)	79,004,006	(10,427,092)
Total assets, net of depreciation and amortization		22,605,707		22,605,707		$ 12,461,676
Capital expenditures		23,247		31,417	1,847
Other expenses (4)	[4]		(851,637)		1,664,265
Equity in loss of R-NAV, LLC					(15,159)
UNITED STATES
Tc 99m tilmanocept sales revenue
Total assets, net of depreciation and amortization		22,521,506	11,040,679	22,521,506	11,040,679
Non-US [Member]
Tc 99m tilmanocept sales revenue			17,601		30,800
Total assets, net of depreciation and amortization		84,201	148,921	84,201	148,921
Diagnostics Segment [Member]
Tc99m tilmanocept license revenue			1,295,625	100,000	1,795,625
Grant and other revenue		210,479	500,628	1,200,216	2,051,622
Revenues		210,479	1,813,854	1,300,216	3,878,047
Cost of goods sold, excluding depreciation and amortization			2,889		5,185
Research and development expenses, excluding depreciation and amortization		734,539	671,777	2,255,842	4,410,133
Selling, general and administrative expenses, excluding depreciation and amortization (1)	[1]
Depreciation, Depletion and Amortization, Nonproduction	[2]
Loss from operations (3)	[3]	(524,060)	1,139,188	(955,626)	(537,271)
Other income (4)
Income tax benefit		175,496		323,149
Net loss from continuing operations		(348,564)	1,139,188	(632,477)	(537,271)
Income from discontinued operations, net of tax		5,399	1,701,911	(332,838)	(5,167,312)
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax		145,877		86,894,000
Net income		(197,288)	2,841,099	85,928,685	(5,704,583)
Capital expenditures
Other expenses (4)	[4]
Equity in loss of R-NAV, LLC
Diagnostics Segment [Member] | UNITED STATES
Tc 99m tilmanocept sales revenue
Total assets, net of depreciation and amortization		14,675,489	4,950,756	14,675,489	4,950,756
Diagnostics Segment [Member] | Non-US [Member]
Tc 99m tilmanocept sales revenue			17,601		30,800
Total assets, net of depreciation and amortization		82,334	148,224	82,334	148,224
Therapeutics Segment [Member]
Tc99m tilmanocept license revenue
Grant and other revenue		13,190	10,346	115,082	61,798
Revenues		13,190	10,346	115,082	61,798
Cost of goods sold, excluding depreciation and amortization
Research and development expenses, excluding depreciation and amortization		140,008	247,664	509,853	600,790
Selling, general and administrative expenses, excluding depreciation and amortization (1)	[1]	13,359	27,758	19,342	31,590
Depreciation, Depletion and Amortization, Nonproduction	[2]
Loss from operations (3)	[3]	(140,177)	(265,076)	(414,113)	(570,582)
Other income (4)
Income tax benefit		46,942		140,034
Net loss from continuing operations		(93,235)	(265,076)	(274,079)	(570,582)
Income from discontinued operations, net of tax
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax
Net income		(93,235)	(265,076)	(274,079)	(570,582)
Capital expenditures
Other expenses (4)	[4]
Equity in loss of R-NAV, LLC
Therapeutics Segment [Member] | UNITED STATES
Tc 99m tilmanocept sales revenue
Total assets, net of depreciation and amortization		10,591	9,356	10,591	9,356
Therapeutics Segment [Member] | Non-US [Member]
Tc 99m tilmanocept sales revenue
Total assets, net of depreciation and amortization
Corporate Segment [Member]
Tc99m tilmanocept license revenue
Grant and other revenue
Revenues
Cost of goods sold, excluding depreciation and amortization
Research and development expenses, excluding depreciation and amortization
Selling, general and administrative expenses, excluding depreciation and amortization (1)	[1]	1,671,022	1,694,073	8,789,728	5,542,034
Depreciation, Depletion and Amortization, Nonproduction	[2]	50,326	89,849	197,655	258,999
Loss from operations (3)	[3]	(1,721,348)	(1,783,922)	(8,987,383)	(5,801,033)
Other income (4)		69,071		(1,061,190)
Income tax benefit		553,312		3,397,972
Net loss from continuing operations		(1,098,965)	(2,635,559)	(6,650,601)	(4,151,927)
Income from discontinued operations, net of tax
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax
Net income		(1,098,965)	(2,635,559)	(6,650,601)	(4,151,927)
Capital expenditures		23,247		31,417	1,847
Other expenses (4)	[4]		(851,637)		1,664,265
Equity in loss of R-NAV, LLC					(15,159)
Corporate Segment [Member] | UNITED STATES
Tc 99m tilmanocept sales revenue
Total assets, net of depreciation and amortization		7,835,426	6,080,567	7,835,426	6,080,567
Corporate Segment [Member] | Non-US [Member]
Tc 99m tilmanocept sales revenue
Total assets, net of depreciation and amortization		$ 1,867	$ 697	$ 1,867	$ 697
[1]	General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments.
[2]	Depreciation and amortization is reflected in selling, general and administrative expenses ($50,326 and $89,849 for the three-month periods ended September 30, 2017 and 2016 and $197,655 and $258,999 for the nine-month periods ended September 30, 2017 and 2016, respectively).
[3]	Income (loss) from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments.
[4]	Amounts consist primarily of changes in fair value of financial instruments and losses on debt extinguishment, which are not currently allocated to our individual reportable segments.

Note 17 - Supplemental Disclo58

Note 17 - Supplemental Disclosure for Statements of Cash Flows (Details Textual) - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended	9 Months Ended
	Jan. 31, 2017	Mar. 31, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Interest Paid				$ 7,400,000	$ 4,200,000
Reclassification of Funds Invested	$ 200,000			$ 200,000
Stock Issued During Period, Shares, Employee Benefit Plan				105,308	67,002
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution				$ 53,707	$ 120,800
Series NN Warrants [Member] | UCSD [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,000,000		1,000,000
Class of Warrant or Right, Grants in Period, Estimated Fair Value		$ 334,000		$ 334,000
Capital Royalty Group, Term Loan [Member]
Payments to Collection of Collateral on Claims of Default			$ 778,000		778,000
Payments to Prepayment Premium on Claims of Default			$ 2,100,000		$ 2,100,000